Proactive Investors
13 Jun 2026, 09:45 UTC · 1h ago
Poolbeg Pharma has begun an exciting new clinical trial - ICYMI
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
13 Jun 2026, 09:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Poolbeg Pharma PLC has activated clinical trial sites and begun patient enrolment for its POLB 001 programme to prevent cytokine release syndrome (CRS). — The transition from planning to active patient enrolment is a critical value-inflection milestone for biotech companies.
+0.60Preclinical data for POLB 001, including in vitro and humanised mouse models, showed the drug reduced cytokines and CRS without impairing tumour-killing activity. — Positive preclinical results increase the probability of clinical success, though they are less impactful than human trial data.
+0.40The current POLB 001 study is an open-label, single-arm trial with 30 patients receiving teclistamab, with results expected relatively quickly due to the early onset of CRS. — A small, focused trial with a fast readout provides a clear timeline for the next potential catalyst.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced the start of patient enrollment for its POLB 001 clinical trial and reported overwhelmingly positive results from previous models.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1d ago
